BAXTER INTERNATIONAL INC — Form 8-K
Filed October 29, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 48/100
What the filing says
Baxter reported Q3 2026 sales of $2.98B (up 5% reported and organic), with diluted EPS of $0.57 GAAP and $0.58 adjusted. The company raised full-year 2026 guidance: reported sales growth to 4–5% (from 3–4%), organic growth to 3–4% (from 2–3%), and adjusted EPS to $2.05–$2.15 (from $1.95–$2.15). In Q3, Baxter completed a $600M cash tender offer, retiring $864M of debt and accelerating deleveraging. All segments grew; free cash flow was $448M in Q3 and $705M year-to-date.
Why this rating
Guidance raise and debt reduction are favorable, but modest 3–5% growth on ~$16B market cap is ordinary execution. Deleveraging supports stability, not transformation. Routine earnings beat.
See more from October 29, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.